Anavex Life Sciences (AVXL) Financials

$7.70 +0.12 (+1.60%)

As of 01:02 PM Eastern

Annual Income Statements for Anavex Life Sciences

This table shows Anavex Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	9/30/2024	9/30/2023	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-43	-48	-48
Consolidated Net Income / (Loss)	-43	-48	-48
Net Income / (Loss) Continuing Operations	-43	-48	-48
Total Pre-Tax Income	-43	-47	-48
Total Operating Income	-53	-56	-51
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	53	56	51
Selling, General & Admin Expense	11	12	13
Research & Development Expense	42	44	38
Total Other Income / (Expense), net	9.88	8.26	3.37
Interest Expense	-7.32	-6.52	-0.95
Interest & Investment Income	2.29	2.72	3.32
Other Income / (Expense), net	0.26	-0.98	-0.90
Income Tax Expense	0.00	0.01	0.36
Basic Earnings per Share	($0.52)	($0.60)	-
Weighted Average Basic Shares Outstanding	83.47M	79.79M	-0.62
Diluted Earnings per Share	($0.52)	($0.60)	-
Weighted Average Diluted Shares Outstanding	83.47M	79.79M	-0.62
Weighted Average Basic & Diluted Shares Outstanding	84.82M	82.09M	-0.62

This table shows Anavex Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-12	-12	-12	-11	-8.62	-10	-11	-13	-13	-14	-12
Consolidated Net Income / (Loss)	-12	-12	-12	-11	-8.62	-10	-11	-13	-13	-14	-12
Net Income / (Loss) Continuing Operations	-12	-12	-12	-11	-8.62	-10	-11	-13	-13	-14	-12
Total Pre-Tax Income	-12	-12	-12	-10	-8.62	-10	-11	-13	-13	-14	-12
Total Operating Income	-14	-14	-15	-13	-11	-13	-14	-14	-15	-15	-12
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	14	14	15	13	11	13	14	14	15	15	12
Selling, General & Admin Expense	3.15	2.78	2.86	2.79	2.69	2.59	3.25	2.88	3.32	3.90	3.19
Research & Development Expense	10	12	12	9.73	8.68	10	10	11	12	11	9.27
Total Other Income / (Expense), net	1.48	2.59	2.45	2.08	2.76	2.44	2.29	1.13	2.39	1.20	0.18
Interest Expense	-1.39	-1.70	-1.86	-1.76	-2.01	-1.96	-1.83	-1.47	-1.27	-0.70	-0.23
Interest & Investment Income	0.41	0.70	0.53	0.47	0.59	0.67	0.57	0.75	0.73	0.99	0.68
Other Income / (Expense), net	-0.33	0.19	0.07	-0.15	0.16	-0.19	-0.10	-1.08	0.39	-0.50	-0.73
Basic Earnings per Share	($0.14)	-	($0.14)	($0.13)	($0.11)	-	($0.14)	($0.17)	-	-	-
Weighted Average Basic Shares Outstanding	84.81M	83.47M	84.54M	82.46M	82.08M	79.79M	80.88M	78.30M	77.98M	-0.62	-0.16
Diluted Earnings per Share	($0.14)	-	($0.14)	($0.13)	($0.11)	-	($0.14)	($0.17)	-	-	-
Weighted Average Diluted Shares Outstanding	84.81M	83.47M	84.54M	82.46M	82.08M	79.79M	80.88M	78.30M	77.98M	-0.62	-0.16
Weighted Average Basic & Diluted Shares Outstanding	85.06M	84.82M	84.80M	84.64M	82.11M	82.09M	-0.14	78.30M	77.98M	-0.62	77.44M

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	9/30/2024	9/30/2023	9/30/2022
Net Change in Cash & Equivalents	-19	1.87	-2.95
Net Cash From Operating Activities	-31	-28	-24
Net Cash From Continuing Operating Activities	-31	-28	-24
Net Income / (Loss) Continuing Operations	-43	-48	-48
Consolidated Net Income / (Loss)	-43	-48	-48
Non-Cash Adjustments To Reconcile Net Income	9.36	17	18
Changes in Operating Assets and Liabilities, net	2.83	2.51	5.36
Net Cash From Investing Activities	0.00	0.00	0.00
Net Cash From Continuing Investing Activities	0.00	0.00	0.00
Net Cash From Financing Activities	12	30	21
Net Cash From Continuing Financing Activities	12	30	21
Issuance of Common Equity	11	28	21
Other Financing Activities, net	0.69	1.78	1.01

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Net Change in Cash & Equivalents	-11	-6.57	-0.63	-4.38	-7.26	-3.79	1.35	9.85	-5.54	-4.04	-0.14
Net Cash From Operating Activities	-12	-6.66	-5.18	-12	-7.32	-5.85	-7.65	-8.49	-5.79	-4.04	-7.05
Net Cash From Continuing Operating Activities	-12	-6.66	-5.18	-12	-7.32	-5.85	-7.65	-8.49	-5.79	-4.04	-7.05
Net Income / (Loss) Continuing Operations	-12	-12	-12	-11	-8.62	-10	-11	-13	-13	-14	-12
Consolidated Net Income / (Loss)	-12	-12	-12	-11	-8.62	-10	-11	-13	-13	-14	-12
Non-Cash Adjustments To Reconcile Net Income	2.06	2.00	2.43	2.65	2.29	3.19	3.87	4.82	5.35	6.04	3.99
Changes in Operating Assets and Liabilities, net	-2.06	2.97	4.61	-3.76	-0.98	1.11	-0.24	-0.20	1.83	4.20	1.33
Net Cash From Investing Activities	0.00	-	-	-	0.00	-	-	-	0.00	-	-
Net Cash From Continuing Investing Activities	0.00	-	-	-	0.00	-	-	-	0.00	-	-
Net Cash From Financing Activities	0.71	0.09	4.55	7.28	0.06	2.06	9.00	18	0.26	0.00	6.91
Net Cash From Continuing Financing Activities	0.71	0.09	4.55	7.28	0.06	2.06	9.00	18	0.26	0.00	6.91
Other Financing Activities, net	0.71	0.09	0.44	0.10	0.06	0.87	0.47	0.18	0.26	-0.00	0.51

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	9/30/2024	9/30/2023	9/30/2022
Total Assets	136	154	153
Total Current Assets	133	152	153
Cash & Equivalents	132	151	149
Prepaid Expenses	0.93	0.65	0.35
Plant, Property, & Equipment, net	0.00	0.00	0.00
Total Noncurrent Assets	2.45	2.71	0.00
Noncurrent Note & Lease Receivables	2.45	2.71	-
Total Liabilities & Shareholders' Equity	136	154	153
Total Liabilities	15	13	10
Total Current Liabilities	14	12	9.77
Accounts Payable	9.63	4.32	3.83
Accrued Expenses	4.84	7.30	5.95
Total Noncurrent Liabilities	0.84	0.92	0.44
Other Noncurrent Operating Liabilities	0.84	-	0.44
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	120	142	142
Total Preferred & Common Equity	120	142	142
Preferred Stock	0.00	0.00	0.00
Total Common Equity	120	142	142
Common Stock	456	435	388
Retained Earnings	-336	-293	-246

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	12/31/2024	6/30/2024	3/31/2024	12/31/2023	6/30/2023	3/31/2023	12/31/2022	6/30/2022
Total Assets	124	142	145	148	158	159	148	160
Total Current Assets	121	142	141	145	156	159	148	160
Cash & Equivalents	121	139	139	144	155	153	144	153
Prepaid Expenses	0.71	1.06	1.35	0.76	0.83	0.98	0.66	0.46
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	2.56	0.00	3.79	3.55	2.17	0.00	0.00	0.00
Noncurrent Note & Lease Receivables	2.56	-	3.79	3.55	2.17	-	-	-
Total Liabilities & Shareholders' Equity	124	142	145	148	158	159	148	160
Total Liabilities	13	12	9.56	12	11	14	13	9.48
Total Current Liabilities	12	11	8.64	12	10	13	12	9.48
Accounts Payable	4.57	3.50	3.73	4.29	4.15	6.28	5.29	3.13
Accrued Expenses	7.73	7.33	4.92	7.29	5.99	6.82	7.04	5.91
Total Noncurrent Liabilities	0.83	0.92	0.92	0.92	0.92	0.92	0.92	0.00
Other Noncurrent Operating Liabilities	0.83	0.92	0.92	0.92	0.92	0.92	0.92	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	111	130	135	136	147	145	135	151
Total Preferred & Common Equity	111	130	135	136	147	145	135	151
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	111	130	135	136	147	145	135	151
Common Stock	459	454	447	437	430	417	394	382
Retained Earnings	-348	-324	-312	-302	-283	-272	-259	-231

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric	2024	2023	2022
Period end date	9/30/2024	9/30/2023	9/30/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	7.27%	-9.34%	-22.92%
EBIT Growth	7.27%	-9.34%	-22.92%
NOPAT Growth	5.16%	-9.36%	-21.39%
Net Income Growth	9.48%	0.99%	-26.56%
EPS Growth	13.33%	0.00%	0.00%
Operating Cash Flow Growth	-10.89%	-14.63%	20.23%
Free Cash Flow Firm Growth	6.19%	-20.49%	-0.63%
Invested Capital Growth	-30.00%	-37.57%	-416.97%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-2.55%	4.93%	-6.67%
EBIT Q/Q Growth	-2.55%	4.93%	-6.67%
NOPAT Q/Q Growth	-3.29%	4.51%	-6.32%
Net Income Q/Q Growth	-3.55%	8.02%	-5.66%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-2.70%	-6.95%	13.03%
Free Cash Flow Firm Q/Q Growth	1.89%	-3.55%	3.83%
Invested Capital Q/Q Growth	-32.86%	-13.76%	-170.71%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.01%	100.75%
Interest Burden Percent	81.73%	83.72%	91.77%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-32.81%	-33.41%	-32.72%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-32.81%	-33.41%	-32.72%
Return on Equity Simple (ROE_SIMPLE)	-35.76%	-33.49%	-33.67%
Net Operating Profit after Tax (NOPAT)	-37	-39	-36
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.23%	-5.65%	-8.16%
Return On Investment Capital (ROIC_SIMPLE)	-30.78%	-27.51%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-53	-57	-52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-53	-57	-52
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.00	3.78	5.65
Price to Tangible Book Value (P/TBV)	4.00	3.78	5.65
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.08	-1.06	-1.03
Leverage Ratio	1.11	1.08	1.07
Compound Leverage Factor	0.90	0.90	0.98
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	15.18	22.91	45.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.20	13.06	15.63
Quick Ratio	9.14	13.00	15.27
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-34	-37	-30
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-12	-9.17	-6.67
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-2.75	-2.51	-5.38
Enterprise Value (EV)	349	386	655
Market Capitalization	482	537	804
Book Value per Share	$1.42	$1.73	$1.83
Tangible Book Value per Share	$1.42	$1.73	$1.83
Total Capital	120	142	142
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-132	-151	-149
Capital Expenditures (CapEx)	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-11	-6.22
Debt-free Net Working Capital (DFNWC)	119	140	143
Net Working Capital (NWC)	119	140	143
Net Nonoperating Expense (NNE)	5.99	8.48	12
Net Nonoperating Obligations (NNO)	-132	-151	-149
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.52)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	83.47M	82.09M	77.96M
Adjusted Diluted Earnings per Share	($0.52)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	83.47M	82.09M	77.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	84.82M	82.09M	76.91M
Normalized Net Operating Profit after Tax (NOPAT)	-37	-39	-36
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-1.47%

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-24.02%	-10.18%	-7.56%	17.04%	25.15%	18.64%	-3.34%	-35.74%	-28.50%	-25.88%	-14.54%
EBIT Growth	-24.02%	-10.18%	-7.56%	17.04%	25.15%	18.64%	-3.34%	-35.74%	-28.50%	-25.88%	-14.54%
NOPAT Growth	-19.46%	-13.32%	-8.85%	11.78%	26.04%	17.23%	-8.61%	-23.18%	-31.22%	-24.74%	-9.30%
Net Income Growth	-40.47%	-14.53%	-8.28%	19.54%	33.53%	29.00%	8.79%	-25.57%	-19.20%	-21.95%	-21.49%
EPS Growth	-27.27%	0.00%	0.00%	23.53%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-65.62%	-13.83%	32.31%	-37.31%	-26.30%	-44.63%	-8.50%	11.94%	-65.50%	47.31%	6.22%
Free Cash Flow Firm Growth	5.17%	-14.68%	-142.72%	-356.45%	-17.34%	-19.34%	41.97%	60.31%	-57.20%	42.78%	36.47%
Invested Capital Growth	-20.39%	-30.00%	-11.32%	46.66%	3.62%	-37.57%	-227.38%	-629.83%	-77.83%	-416.97%	-494.41%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	1.61%	3.53%	-15.73%	-13.76%	12.59%	5.82%	10.74%	-1.86%	4.98%	-19.62%	-17.24%
EBIT Q/Q Growth	1.61%	3.53%	-15.73%	-13.76%	12.59%	5.82%	10.74%	-1.86%	4.98%	-19.62%	-17.24%
NOPAT Q/Q Growth	5.19%	2.67%	-17.65%	-10.86%	10.06%	6.50%	4.64%	7.76%	-0.65%	-22.68%	-8.15%
Net Income Q/Q Growth	-4.23%	4.86%	-15.82%	-22.32%	15.02%	10.05%	13.94%	-1.04%	9.23%	-15.55%	-18.49%
EPS Q/Q Growth	0.00%	0.00%	-7.69%	0.00%	0.00%	0.00%	17.65%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-82.04%	-28.53%	55.56%	-59.28%	-25.12%	23.57%	9.85%	-46.51%	-43.27%	42.67%	26.83%
Free Cash Flow Firm Q/Q Growth	-7.71%	22.50%	25.63%	-53.87%	-30.26%	-64.02%	-39.85%	60.73%	-32.47%	20.25%	4.34%
Invested Capital Q/Q Growth	17.31%	-32.86%	-102.69%	45.93%	10.71%	-13.76%	2.88%	2.30%	-27.46%	-170.71%	-116.50%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	98.95%	99.45%	101.01%	100.00%	99.37%	100.36%	100.38%	99.85%	101.49%	100.72%
Interest Burden Percent	87.02%	83.02%	83.76%	82.41%	76.83%	79.53%	82.45%	85.50%	86.65%	89.23%	93.08%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-37.72%	-32.81%	-30.03%	-28.98%	-31.88%	-33.41%	-34.72%	-35.47%	-35.57%	-32.72%	-29.50%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-37.72%	-32.81%	-30.03%	-28.98%	-31.88%	-33.41%	-34.72%	-35.47%	-35.57%	-32.72%	-29.50%
Return on Equity Simple (ROE_SIMPLE)	-41.92%	0.00%	-32.00%	-30.08%	-31.83%	0.00%	-35.19%	-36.33%	-37.05%	0.00%	-30.12%
Net Operating Profit after Tax (NOPAT)	-9.51	-10	-10	-8.76	-7.96	-8.86	-9.47	-9.93	-11	-11	-8.72
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-1.96%	-1.12%	-1.30%	-1.22%	-0.46%	-0.86%	-1.17%	-2.07%	-1.49%	-2.38%	-2.35%
Return On Investment Capital (ROIC_SIMPLE)	-8.58%	-8.34%	-	-	-5.87%	-6.24%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-14	-14	-15	-13	-11	-13	-14	-15	-15	-16	-13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-14	-15	-13	-11	-13	-14	-15	-15	-16	-13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.21	4.00	2.75	3.10	5.63	3.78	4.48	4.61	5.34	5.65	5.14
Price to Tangible Book Value (P/TBV)	8.21	4.00	2.75	3.10	5.63	3.78	4.48	4.61	5.34	5.65	5.14
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.07	-1.08	-1.06	-1.05	-1.06	-1.06	-1.04	-1.03	-1.05	-1.03	-1.01
Leverage Ratio	1.10	1.11	1.08	1.08	1.10	1.08	1.07	1.07	1.08	1.07	1.06
Compound Leverage Factor	0.96	0.92	0.91	0.89	0.84	0.86	0.88	0.92	0.94	0.96	0.99
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	38.39	16.12	15.79	24.02	34.61	23.85	33.98	27.01	31.02	45.78	47.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.88	9.20	13.06	16.29	12.48	13.06	15.35	12.15	12.03	15.63	16.89
Quick Ratio	9.82	9.14	12.80	16.13	12.42	13.00	15.27	11.71	11.65	15.27	16.15
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-7.84	-7.28	-9.40	-13	-8.27	-6.35	-3.87	-2.77	-7.05	-5.32	-6.67
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-9.86	-12	-8.98	-4.43	-8.19	-9.17	-8.06	-8.30	-8.50	-6.67	-2.46
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-1.67	-2.75	-0.91	3.87	0.31	-2.51	-5.60	-7.16	-3.72	-5.38	-2.05
Enterprise Value (EV)	790	349	218	279	619	386	502	515	578	655	622
Market Capitalization	911	482	357	418	763	537	657	669	722	804	775
Book Value per Share	$1.31	$1.42	$1.53	$1.64	$1.65	$1.73	$1.82	$1.86	$1.73	$1.83	$1.95
Tangible Book Value per Share	$1.31	$1.42	$1.53	$1.64	$1.65	$1.73	$1.82	$1.86	$1.73	$1.83	$1.95
Total Capital	111	120	130	135	136	142	147	145	135	142	151
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-121	-132	-139	-139	-144	-151	-155	-153	-144	-149	-153
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-12	-14	-8.06	-7.30	-11	-11	-9.31	-7.39	-7.58	-6.22	-2.46
Debt-free Net Working Capital (DFNWC)	109	119	131	132	133	140	146	146	136	143	151
Net Working Capital (NWC)	109	119	131	132	133	140	146	146	136	143	151
Net Nonoperating Expense (NNE)	2.60	1.58	1.90	1.78	0.66	1.29	1.81	3.17	2.20	3.59	3.65
Net Nonoperating Obligations (NNO)	-121	-132	-139	-139	-144	-151	-155	-153	-144	-149	-153
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.14)	$0.00	($0.14)	($0.13)	$0.00	$0.00	$0.00	($0.17)	($0.17)	$0.00	($0.16)
Adjusted Weighted Average Basic Shares Outstanding	84.81M	83.47M	84.54M	82.46M	82.11M	79.79M	81.95M	80.84M	78.03M	-1.00	77.94M
Adjusted Diluted Earnings per Share	($0.14)	$0.00	($0.14)	($0.13)	$0.00	$0.00	$0.00	($0.17)	($0.17)	$0.00	($0.16)
Adjusted Weighted Average Diluted Shares Outstanding	84.81M	83.47M	84.54M	82.46M	82.11M	79.79M	81.95M	80.84M	78.03M	-1.00	77.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.17)	($0.17)	$0.00	($0.16)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	85.06M	84.82M	84.80M	84.64M	82.11M	82.09M	80.88M	78.30M	77.98M	-1.00	77.44M
Normalized Net Operating Profit after Tax (NOPAT)	-9.51	-10	-10	-8.76	-7.96	-8.86	-9.47	-9.93	-11	-11	-8.72
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.47%	0.00%

Frequently Asked Questions About Anavex Life Sciences' Financials

When does Anavex Life Sciences's fiscal year end?

According to the most recent income statement we have on file, Anavex Life Sciences' financial year ends in September. Their financial year 2024 ended on September 30, 2024.

How has Anavex Life Sciences' net income changed over the last 2 years?

Anavex Life Sciences' net income appears to be on a downward trend, with a most recent value of -$43.00 million in 2024, falling from -$47.98 million in 2022. The previous period was -$47.51 million in 2023. See Anavex Life Sciences' forecast for analyst expectations on what’s next for the company.

What is Anavex Life Sciences's operating income?

Anavex Life Sciences's total operating income in 2024 was -$52.88 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $52.88 million

How has Anavex Life Sciences revenue changed over the last 2 years?

Over the last 2 years, Anavex Life Sciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Anavex Life Sciences have?

Anavex Life Sciences' total liabilities were at $15.30 million at the end of 2024, a 22.1% increase from 2023, and a 49.8% increase since 2022.

How much cash does Anavex Life Sciences have?

In the past 2 years, Anavex Life Sciences' cash and equivalents has ranged from $132.19 million in 2024 to $151.02 million in 2023, and is currently $132.19 million as of their latest financial filing in 2024.

How has Anavex Life Sciences' book value per share changed over the last 2 years?

Over the last 2 years, Anavex Life Sciences' book value per share changed from 1.83 in 2022 to 1.42 in 2024, a change of -22.4%.

Related Companies

This page (NASDAQ:AVXL) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Financials

Frequently Asked Questions About Anavex Life Sciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Financials

Annual Income Statements for Anavex Life Sciences

Quarterly Income Statements for Anavex Life Sciences

Annual Cash Flow Statements for Anavex Life Sciences

Quarterly Cash Flow Statements for Anavex Life Sciences

Annual Balance Sheets for Anavex Life Sciences

Quarterly Balance Sheets for Anavex Life Sciences

Annual Metrics And Ratios for Anavex Life Sciences

Quarterly Metrics And Ratios for Anavex Life Sciences

Frequently Asked Questions About Anavex Life Sciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools